These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 27301417

  • 1. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H, Mailänder C, Baier M, Kirsten A.
    BMC Pulm Med; 2016 Jun 14; 16(1):95. PubMed ID: 27301417
    [Abstract] [Full Text] [Related]

  • 2. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T.
    Lancet Respir Med; 2018 May 14; 6(5):368-378. PubMed ID: 29477448
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.
    Int J Chron Obstruct Pulmon Dis; 2014 May 14; 9():215-28. PubMed ID: 24596459
    [Abstract] [Full Text] [Related]

  • 4. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.
    Respir Med; 2014 Apr 14; 108(4):584-92. PubMed ID: 24534204
    [Abstract] [Full Text] [Related]

  • 5. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P, Hagedorn-Peinz I.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr 14; 13():69-77. PubMed ID: 29317812
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R.
    Respir Med; 2016 Jun 14; 115():39-45. PubMed ID: 27215502
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.
    Respir Res; 2017 Jan 11; 18(1):13. PubMed ID: 28077140
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Jan 11; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV, FLASH Investigators.
    Respirology; 2018 Dec 11; 23(12):1152-1159. PubMed ID: 30074294
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.
    Respir Med; 2013 Oct 11; 107(10):1558-67. PubMed ID: 23867808
    [Abstract] [Full Text] [Related]

  • 17. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
    van Geffen WH, Carpaij OA, Westbroek LF, Seigers D, Niemeijer A, Vonk JM, Kerstjens HAM.
    Respir Med; 2020 Sep 11; 171():106064. PubMed ID: 32917359
    [Abstract] [Full Text] [Related]

  • 18. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM, Wagner F, Khindri S, Drollmann AF.
    COPD; 2011 Oct 11; 8(5):340-5. PubMed ID: 21793716
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.